Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)

被引：0

作者：

Liu, Xiufeng ^{[1
]}

Lu, Yinying ^{[2
]}

Zhou, Weiping ^{[3
]}

Peng, Tao ^{[4
]}

Zhou, Jie ^{[5
]}

Bi, Huaqiang ^{[6
]}

Xia, Feng ^{[6
]}

Chen, Xiaoping ^{[7
]}

机构：

[1] Jinling Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Peoples R China

[2] Peoples Liberat Army Gen Hosp, Comprehens Liver Canc Ctr, Med Ctr 5, Beijing, Peoples R China

[3] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 3, Shanghai, Peoples R China

[4] Guangxi Med Univ, Affiliated Hosp 1, Hepatobiliary Surg Dept, Nanning, Peoples R China

[5] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Div Hepatobiliopancreat Surg & Liver Transplantat, Guangzhou, Peoples R China

[6] Army Med Univ, Hosp 1, Dept Hepatobiliary Surg, Chongqing, Peoples R China

[7] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan, Peoples R China

来源：

LIVER CANCER | 2024年 / 13卷 / 04期

关键词：

Hepatocellular carcinoma; Immunotherapy; Combination therapy; Immune checkpoint inhibitors; Multidisciplinary team; Consensus; TENOFOVIR DISOPROXIL FUMARATE; OPEN-LABEL; DOUBLE-BLIND; CONVERSION THERAPY; SINTILIMAB PLUS; SORAFENIB; PHASE-3; IMMUNOTHERAPY; ATEZOLIZUMAB; MULTICENTER;

D O I：

10.1159/000535496

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. Summary: To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the "Delphi" consensus formation method, and finally revised and completed the "Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 edition. Key Messages: This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.

引用

页码：355 / 375

页数：21

共 50 条

[31] Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Cheng, Ann-Lii
Hsu, Chiun
Chan, Stephen L.
Choo, Su-Pin
Kudo, Masatoshi
JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 307 - 319
[32] Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Ruff, Samantha M.
Manne, Ashish
Cloyd, Jordan M.
Dillhoff, Mary
Ejaz, Aslam
Pawlik, Timothy M.
CURRENT ONCOLOGY, 2023, 30 (06) : 5863 - 5875
[33] Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Machairas, Nikolaos
Tsilimigras, Diamantis, I
Pawlik, Timothy M.
CANCERS, 2022, 14 (08)
[34] Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Sun, Yongkun
Zhang, Wen
Bi, Xinyu
Yang, Zhengqiang
Tang, Yu
Jiang, Liming
Bi, Feng
Chen, Minshan
Cheng, Shuqun
Chi, Yihebali
Han, Yue
Huang, Jing
Huang, Zhen
Ji, Yuan
Jia, Liqun
Jiang, Zhichao
Jin, Jing
Jin, Zhengyu
Li, Xiao
Li, Zhiyu
Liang, Jun
Liu, Lianxin
Liu, Yunpeng
Lu, Yinying
Lu, Shichun
Meng, Qinghua
Niu, Zuoxing
Pan, Hongming
Qin, Shukui
Qu, Wang
Shao, Guoliang
Shen, Feng
Song, Tianqiang
Song, Yan
Tao, Kaishan
Tian, Aiping
Wang, Jianhua
Wang, Wenling
Wang, Zhe
Wu, Liqun
Xia, Feng
Xing, Baocai
Xu, Jianming
Xue, Huadan
Yan, Dong
Yang, Lin
Ying, Jianming
Yun, Jingping
Zeng, Zhaochong
Zhang, Xuewen
LIVER CANCER, 2022, 11 (03) : 192 - 208
[35] Immune checkpoint inhibitor-based therapy for advanced acral and mucosal melanoma
Mori, Tatsuhiko
Izumi, Teruaki
Doi, Reiichi
Kamimura, Anna
Takai, Sayaka
Teramoto, Yukiko
Nakamura, Yasuhiro
EXPERIMENTAL DERMATOLOGY, 2023, 32 (03) : 276 - 289
[36] Immune checkpoint inhibitor-based therapy: assessing the risk of pulmonary toxicity
Reactions Weekly, 2023, 1983 (1) : 11 - 11
[37] IMPACT OF CORTICOSTEROID ADMINISTRATION ON TREATMENT EFFECTIVENESS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH IMMUNE CHECKPOINT INHIBITOR-BASED COMBINATION THERAPY
Yoshino, Maki
Ishihara, Hiroki
Nagahisa, Chika
Nemoto, Yuki
Ishiyama, Ryo
Ikeda, Takeshi
Kobari, Yuki
Tachibana, Hidekazu
Fukuda, Hironori
Yoshida, Kazuhiko
Shimmura, Hiroaki
Hashimoto, Yasunobu
Kondo, Tsunenori
Takagi, Toshio
JOURNAL OF UROLOGY, 2024, 211 (05): : E146 - E147
[38] Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Carcinoma
Ishihara, Hiroki
Nemoto, Yuki
Tachibana, Hidekazu
Ikeda, Takashi
Fukuda, Hironori
Yoshida, Kazuhiko
Kobayashi, Hirohito
Iizuka, Junpei
Shimmura, Hiroaki
Hashimoto, Yasunobu
Kondo, Tsunenori
Takagi, Toshio
CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 549 - 557.e5
[39] Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review
Liu, Yi-Fu
Zhang, Zhi-Cheng
Wang, Si-Yuan
Fu, Sheng-Qiang
Cheng, Xiao-Feng
Chen, Ru
Sun, Ting
INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 110
[40] Chinese expert consensus on the diagnosis and treatment of hepatocellular carcinoma with microvascular invasion (2024 edition)
Sun, Juxian
Xia, Yong
Shen, Feng
Cheng, Shuqun
Chinese Association Liver Cancer Chinese Medical Doctor Association
HEPATOBILIARY SURGERY AND NUTRITION, 2024,

← 1 2 3 4 5 →